Icosavax to Participate in the William Blair Biotech Focus Conference

SEATTLE, July 06, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX ), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in the William Blair Biotech Focus Conference taking place from July 12-13, 2022, in New York. Adam Simpson, Chief Executive Officer of Icosavax, will also participate in a pre-recorded analyst led fireside chat that will be available for replay from 9:00 a.m. ET on July 11, 2022. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.icosavax.com . The webcast replay will be available after the conclusion of the panel discussion for approximately 30 days. About Icosavax Icosavax is a biopharmaceutical company leveraging its innovative VLP platform technology to develop vaccines against infectious diseases, with an ... Full story available on Benzinga.com